Avitas Wealth Management LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Avitas Wealth Management LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 18.1% in the second quarter, Holdings Channel.com reports. The firm owned 29,628 shares of the company’s stock after selling 6,530 shares during the period. Avitas Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,330,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of JNJ. Tennessee Valley Asset Management Partners raised its position in Johnson & Johnson by 3.1% in the 4th quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after purchasing an additional 80 shares during the period. Ninety One SA PTY Ltd raised its holdings in shares of Johnson & Johnson by 21.1% in the fourth quarter. Ninety One SA PTY Ltd now owns 65,877 shares of the company’s stock worth $10,326,000 after buying an additional 11,495 shares during the period. SFE Investment Counsel lifted its stake in shares of Johnson & Johnson by 6.7% during the 4th quarter. SFE Investment Counsel now owns 19,636 shares of the company’s stock worth $3,078,000 after acquiring an additional 1,227 shares during the last quarter. AIA Group Ltd boosted its holdings in Johnson & Johnson by 46.9% during the 4th quarter. AIA Group Ltd now owns 6,706 shares of the company’s stock valued at $1,051,000 after acquiring an additional 2,141 shares during the period. Finally, Xponance Inc. increased its stake in Johnson & Johnson by 9.6% in the fourth quarter. Xponance Inc. now owns 344,420 shares of the company’s stock worth $53,984,000 after purchasing an additional 30,220 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

Johnson & Johnson stock traded up $1.75 during trading hours on Friday, reaching $164.10. The stock had a trading volume of 7,089,147 shares, compared to its average volume of 7,299,449. The company has a market cap of $394.94 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. The business’s 50 day moving average price is $153.92 and its 200-day moving average price is $153.27. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $167.78. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.